

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1.-72. (Canceled)

¹
~~73.~~ (Previously Presented) An isolated polypeptide comprising SEQ ID NO:392.

²
~~74.~~ (Previously Presented) An isolated polypeptide comprising an amino acid sequence having at least 90% identity to SEQ ID NO:392, wherein said polypeptide is over expressed in ovarian cancer relative to normal ovarian tissue, and wherein said polypeptide is not SEQ ID NO:393.

³
~~75.~~ (Previously Presented) An isolated polypeptide comprising amino acid residues 1-27 of SEQ ID NO:392, wherein said polypeptide is over expressed in ovarian cancer relative to normal ovarian tissue.

⁴
~~76.~~ (Previously Presented) An isolated polypeptide comprising amino acid residues 1-27 of SEQ ID NO:392, or a sequence having at least 90% identity to said polypeptide, wherein said polypeptide is over expressed in ovarian cancer relative to normal ovarian tissue.

⁵
~~77.~~ (Previously Presented) An isolated polypeptide comprising an amino acid sequence having at least 90% identity to amino acid residues 1-27 of SEQ ID NO:392, wherein said polypeptide is over expressed in ovarian cancer relative to normal ovarian tissue.

⁶
~~78.~~ (Previously Presented) A fusion polypeptide comprising a polypeptide according to any one of claims ~~73-77.~~ ¹⁻⁵

⁷
~~79.~~ (Previously Presented) A composition comprising a polypeptide according to any one of claims ~~73-77~~ ¹⁻⁵ and at least one physiologically acceptable excipient.

~~80.~~⁸⁰ (Previously Presented) A composition comprising a polypeptide according to any one of claims ~~73-77~~¹⁻⁵ and at least one adjuvant.

~~81.~~⁸¹ (Previously Presented) The composition of claim ~~80~~⁸, wherein the adjuvant is selected from the group consisting of: an MPL, QS21 and AS-2.